Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Fujii T, et al. PLoS One. 2017 Sep 28;12(9):e0185231. doi: 10.1371/journal.pone.0185231. eCollection 2017. PLoS One. 2017. PMID: 28957377 Free PMC article.
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.
Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Kogawa T, et al. Among authors: fujii t. J Cancer. 2015 Jan 22;6(4):310-8. doi: 10.7150/jca.10580. eCollection 2015. J Cancer. 2015. PMID: 25767600 Free PMC article.
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. Kogawa T, et al. Among authors: fujii t. Oncologist. 2016 Jan;21(1):21-7. doi: 10.1634/theoncologist.2015-0101. Epub 2015 Dec 9. Oncologist. 2016. PMID: 26659222 Free PMC article.
Impact of clinical trial on survival outcomes.
Le Du F, Fujii T, Park M, Liu D, Hsu L, Gonzalez-Angulo AM, Ueno NT. Le Du F, et al. Among authors: fujii t. Breast Cancer Res Treat. 2016 Sep;159(2):273-81. doi: 10.1007/s10549-016-3942-5. Epub 2016 Aug 16. Breast Cancer Res Treat. 2016. PMID: 27530453
Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Reyes ME, et al. Among authors: fujii t. Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17. Breast Cancer Res Treat. 2017. PMID: 28417335
6,472 results